Nimbus Migraine Research Summaries
Plain-English summaries of the latest migraine science.
IgG Elimination Diet for Migraine: What a New Trial Found
A 12-week randomized trial in 95 adults found that cutting foods flagged by an IgG blood test reduced migraine days, disability, and inflammation markers including CGRP. Here is what the study actually showed — and why the test behind it remains controversial.
September 3, 2026
Semax for Migraine: What the Evidence Actually Shows (2026)
The FDA's advisory committee voted in July 2026 to recommend Semax for pharmacy compounding — against FDA staff's own recommendation. Here is what the migraine evidence for this peptide actually consists of: one open-label study from 1996 with twelve participants, no control group, and no benefit for most of them.
August 1, 2026
A Plain-English Guide to the Latest Migraine Medications (2025)
A 2025 international guideline reviewed hundreds of clinical trials to determine which migraine medications work best — from triptans and gepants to CGRP monoclonal antibodies — both for stopping attacks and preventing them. Updated August 2026: Reyvow (lasmiditan) has been discontinued worldwide.
April 11, 2026